此外，宜明昂科近期公布，集团独立研发的IMM0306(一种靶向CD47xCD20的原创新药双特异性抗体)治疗视神经脊髓炎谱系疾病的Ib期临床试验成功完成首例患者给药，且并无不良事件报告。截至本公告日期，集团拥有IMM0306的全球知识产权及商业化权利。IMMUNEONCO-B (01541) rose nearly 15% in the early session. As of the time of writing, it is up 14.47%, priced at HKD 5.38, with a trading volume of HKD 96.8599 million.
Zhichun Finance APP has learned that IMMUNEONCO-B (01541) rose nearly 15% in early trading, as of the time of this report, it was up 14.47%, priced at 5.38 HKD, with a transaction volume of 96.8599 million HKD.
In terms of news, IMMUNEONCO announced that it plans to sell all equity of Shanghai Zhangtouyao New Technology Development for a maximum of about 98.19 million yuan to Shanghai Zhangjiang (Group). According to the announcement, Shanghai Zhangtouyao holds industrial land located in the Kangqiao Industrial Park of Pudong New District, Shanghai, with a land area of about 0.028 million square meters. The Group stated that after the completion of the sale, it will strengthen cash flow, and the proceeds from the sale are intended to be used for general working capital.
In addition, IMMUNEONCO recently announced that the Group's independently developed IMM0306 (a novel bispecific antibody targeting CD47xCD20) has successfully completed the administration of the first patient in the Phase Ib clinical trial for treating neuromyelitis optica spectrum disorders, with no adverse event reports. As of the date of this announcement, the Group holds the global intellectual property and commercialization rights for IMM0306.
